pharmaceutics

IMPACT FACTOR 5.4 | Indexed in: PubMed | CITESCORE 6.9

an Open Access Journal by MDPI

Gene- and Cell-Based Therapies for Retinal Diseases

Guest Editors:

Dr. Kerstin Nagel-Wolfrum
Institute of Molecular Physiology, Johannes Gutenberg University, 55099 Mainz, Germany

Dr. Knut Stieger
Department of Ophthalmology, Justus-Liebig-University Giessen, 35390 Giessen, Germany

Deadline for manuscript submissions:
closed (30 November 2022)

Message from the Guest Editors

Dear Colleagues,

Vision loss due to inherited retinal dystrophies is a severe and mostly untreatable burden for 2–4 million patients worldwide. Thus, innovative strategies defeating neuronal dysfunction and cell loss are urgently needed. Gene- and cell-based therapies take center stage in the attempt to find effective ways to treat retinal diseases. In addition, interdisciplinary research approaches to identify factors influencing the outcome of those therapies such as inflammation and vector-related immune responses, and the development of robust and meaningful read-out parameters for upcoming clinical trials are needed.

In this Special Issue, entitled "Gene- and Cell-Based Therapies for Retinal Diseases", we invite scientists to contribute original research or review articles to provide a comprehensive overview of current activities in this field of science and to highlight potential new areas of therapeutic development.

pharmaceutics

IMPACT FACTOR 5.4 | Indexed in: PubMed | CITESCORE 6.9

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
𝕏@MDPIpharma